vs
Side-by-side financial comparison of Ranpak Holdings Corp. (PACK) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $93.7M, roughly 1.9× Ranpak Holdings Corp.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 2.3%). Over the past eight quarters, Ranpak Holdings Corp.'s revenue compounded faster (13.7% CAGR vs -0.2%).
Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PACK vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $93.7M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | 39.0% | — |
| Operating Margin | -1.0% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 2.3% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.11 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $93.7M | $196.9M | ||
| Q3 25 | $83.6M | $179.5M | ||
| Q2 25 | $77.8M | $181.1M | ||
| Q1 25 | $77.6M | $168.9M | ||
| Q4 24 | $91.6M | $187.3M | ||
| Q3 24 | $78.6M | $168.6M | ||
| Q2 24 | $72.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-10.4M | $5.4M | ||
| Q2 25 | $-7.5M | $-4.8M | ||
| Q1 25 | $-10.9M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.1M | $-143.5M | ||
| Q2 24 | $5.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 39.0% | 79.5% | ||
| Q3 25 | 41.1% | 80.9% | ||
| Q2 25 | 37.1% | 77.4% | ||
| Q1 25 | 39.8% | 79.7% | ||
| Q4 24 | 45.2% | 78.7% | ||
| Q3 24 | 43.8% | 76.9% | ||
| Q2 24 | 43.5% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -1.0% | 1.2% | ||
| Q3 25 | -6.8% | 3.5% | ||
| Q2 25 | -12.5% | 4.7% | ||
| Q1 25 | -10.3% | 1.2% | ||
| Q4 24 | 1.5% | 13.2% | ||
| Q3 24 | -5.3% | -82.8% | ||
| Q2 24 | -7.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -12.4% | 3.0% | ||
| Q2 25 | -9.6% | -2.7% | ||
| Q1 25 | -14.0% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -10.3% | -85.1% | ||
| Q2 24 | 7.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.11 | $0.05 | ||
| Q3 25 | $-0.12 | $0.12 | ||
| Q2 25 | $-0.09 | $-0.11 | ||
| Q1 25 | $-0.13 | $0.10 | ||
| Q4 24 | $-0.13 | $0.38 | ||
| Q3 24 | $-0.10 | $-3.11 | ||
| Q2 24 | $0.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $144.3M |
| Total DebtLower is stronger | $401.9M | — |
| Stockholders' EquityBook value | $534.9M | $653.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.75× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $63.0M | $238.4M | ||
| Q3 25 | $49.9M | $246.3M | ||
| Q2 25 | $49.2M | $445.9M | ||
| Q1 25 | $65.5M | $493.6M | ||
| Q4 24 | $76.1M | $484.6M | ||
| Q3 24 | $69.5M | $453.8M | ||
| Q2 24 | $65.1M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $401.9M | $372.2M | ||
| Q3 25 | $403.1M | $376.7M | ||
| Q2 25 | $403.1M | $580.5M | ||
| Q1 25 | $405.2M | $583.4M | ||
| Q4 24 | $406.4M | $585.3M | ||
| Q3 24 | $403.2M | — | ||
| Q2 24 | $396.1M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $534.9M | $693.1M | ||
| Q3 25 | $537.8M | $727.2M | ||
| Q2 25 | $539.0M | $757.8M | ||
| Q1 25 | $544.1M | $798.5M | ||
| Q4 24 | $548.1M | $778.3M | ||
| Q3 24 | $564.3M | $749.6M | ||
| Q2 24 | $566.2M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.75× | 0.54× | ||
| Q3 25 | 0.75× | 0.52× | ||
| Q2 25 | 0.75× | 0.77× | ||
| Q1 25 | 0.74× | 0.73× | ||
| Q4 24 | 0.74× | 0.75× | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.5M | $43.7M | ||
| Q3 25 | $8.5M | $60.8M | ||
| Q2 25 | $-3.6M | $12.0M | ||
| Q1 25 | $-1.3M | $35.5M | ||
| Q4 24 | $6.5M | $33.1M | ||
| Q3 24 | $10.1M | $53.9M | ||
| Q2 24 | $19.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.56× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
